annb0t
Top 20
Key Insights
ResMed's estimated fair value is US$231 based on 2 Stage Free Cash Flow to Equity ResMed is estimated to be 25% undervalued based on current share price of US$174 Analyst price target for RMD is US$190 which is 18% below our fair value estimate
How far off is ResMed Inc. (NYSE:RMD) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present val...
>>> Read more: ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 33% Above Its Share Price
ResMed's estimated fair value is US$231 based on 2 Stage Free Cash Flow to Equity ResMed is estimated to be 25% undervalued based on current share price of US$174 Analyst price target for RMD is US$190 which is 18% below our fair value estimate
How far off is ResMed Inc. (NYSE:RMD) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present val...
>>> Read more: ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 33% Above Its Share Price
